Formic acid dissolves aggregates of an N-terminal huntingtin fragment containing an expanded polyglutamine tract: Applying to quantification of protein components of the aggregates

被引:80
作者
Hazeki, N [1 ]
Tukamoto, T
Goto, J
Kanazawa, I
机构
[1] Japan Sci & Technol Corp, CREST, Tokyo, Japan
[2] Univ Tokyo, Grad Sch Med, Dept Neurol, Div Neurosci,Bunkyo Ku, Tokyo 1138655, Japan
关键词
formic acid; Huntington's disease; proteasome; aggregate;
D O I
10.1006/bbrc.2000.3682
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Huntington's disease (HD) is caused by an expansion of the CAG repeat that encodes polyglutamine in huntingtin, Transient expression of an N-terminal huntingtin fragment containing an expanded polyglutamine tract induced formation of protein aggregates in cultured cells. The turnover of protein components in such aggregates has been difficult to study because of their insolubility in aqueous solutions. Here we describe a method of solubilizing the aggregates and quantifying their protein components. Insoluble pellets were collected from COS7 cells expressing an N-terminal huntingtin fragment containing an expanded polyglutamine tract and subjected to treatment with various detergent, acid, and alkaline reagents. Treatment with 100% formic acid at 37 degreesC for 30 min induced essentially complete dissociation of the aggregates to monomer, We used this solubilization technique to quantify huntingtin fusion protein in the aggregates formed in transient expression experiments. The frequency of aggregate formation increased when the proteasome inhibitor beta -lactone was added to culture media. However, the total amount of accumulated huntingtin fusion protein did not differ between cells cultured with or without beta -lactone, These results suggest that other protein components which are degraded by the proteasome, in addition to huntingtin, might be related to the dynamics of polyglutamine protein aggregates. (C) 2000 Academic Press.
引用
收藏
页码:386 / 393
页数:8
相关论文
共 29 条
[21]   Ataxin-3 with an altered conformation that exposes the polyglutamine domain is associated with the nuclear matrix [J].
Perez, MK ;
Paulson, HL ;
Pittman, RN .
HUMAN MOLECULAR GENETICS, 1999, 8 (13) :2377-2385
[22]   Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment [J].
Persichetti, F ;
Trettel, F ;
Huang, CC ;
Fraefel, C ;
Timmers, HTM ;
Gusella, JF ;
MacDonald, ME .
NEUROBIOLOGY OF DISEASE, 1999, 6 (05) :364-375
[23]   GLUTAMINE REPEATS AS POLAR ZIPPERS - THEIR POSSIBLE ROLE IN INHERITED NEURODEGENERATIVE DISEASES [J].
PERUTZ, MF ;
JOHNSON, T ;
SUZUKI, M ;
FINCH, JT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (12) :5355-5358
[24]   Intranuclear neuronal inclusions: A common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? [J].
Ross, CA .
NEURON, 1997, 19 (06) :1147-1150
[25]   Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo [J].
Scherzinger, E ;
Lurz, R ;
Turmaine, M ;
Mangiarini, L ;
Hollenbach, B ;
Hasenbank, R ;
Bates, GP ;
Davies, SW ;
Lehrach, H ;
Wanker, EE .
CELL, 1997, 90 (03) :549-558
[26]   Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures [J].
Skinner, PJ ;
Koshy, BT ;
Cummings, CJ ;
Klement, IA ;
Helin, K ;
Servadio, A ;
Zoghbi, HY ;
Orr, HT .
NATURE, 1997, 389 (6654) :971-974
[27]   Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone [J].
Stenoien, DL ;
Cummings, CJ ;
Adams, HP ;
Mancini, MG ;
Patel, K ;
DeMartino, GN ;
Marcelli, M ;
Weigel, NL ;
Mancini, MA .
HUMAN MOLECULAR GENETICS, 1999, 8 (05) :731-741
[28]   POLYGLUTAMINE EXPANSION AS A PATHOLOGICAL EPITOPE IN HUNTINGTONS-DISEASE AND 4 DOMINANT CEREBELLAR ATAXIAS [J].
TROTTIER, Y ;
LUTZ, Y ;
STEVANIN, G ;
IMBERT, G ;
DEVYS, D ;
CANCEL, G ;
SAUDOU, F ;
WEBER, C ;
DAVID, G ;
TORA, L ;
AGID, Y ;
BRICE, A ;
MANDEL, JL .
NATURE, 1995, 378 (6555) :403-406
[29]  
Wanker EE, 1999, METHOD ENZYMOL, V309, P375